PMID- 14959845
OWN - NLM
STAT- MEDLINE
DCOM- 20040909
LR  - 20191108
IS  - 1042-8194 (Print)
IS  - 1026-8022 (Linking)
VI  - 44
IP  - 12
DP  - 2003 Dec
TI  - Dendritic cell-based immunotherapy in multiple myeloma.
PG  - 2031-8
AB  - Most patients with multiple myeloma (MM) cannot be cured with currently available 
      therapies. Although complete remission could be achieved in about 50% of newly 
      diagnosed patients with high-dose chemotherapy and tandem transplantation, 
      relapses of the underlying disease occur frequently. To realize long-term 
      disease-free survival, it will be necessary to develop complementary therapies 
      that are non-cross-resistant with chemotherapy. To this end, immunotherapy aimed 
      at inducing or enhancing tumor-specific immunity that may control or eradicate 
      remaining tumor cells may be an appealing method. Dendritic cells (DCs) are 
      professional antigen-presenting cells and considered the best natural adjuvants 
      for immunotherapy in malignancies. Vaccination with tumor antigen-pulsed DCs has 
      been shown to be protective and therapeutic in animal tumor models, and induced a 
      strong tumor-specific immunity and durable tumor regression in human solid tumors 
      and B-cell lymphoma. As a result, clinical trials in various human malignancies 
      have been initiated. This review will focus on DC-based immunotherapy in MM. I 
      will discuss myeloma antigens and antigen-specific immune responses, the capacity 
      of DCs to present myeloma antigens and induce cytotoxic T-cell responses, and 
      clinical experience of DC vaccination in myeloma patients.
FAU - Yi, Qing
AU  - Yi Q
AD  - Myeloma Institute for Research and Therapy, Arkansas Cancer Research Center 
      University of Arkansas for Medical Sciences, 4301 West Markham Street, Slot #776, 
      Little Rock, AR 72205, USA. yiqing@uams.edu
LA  - eng
GR  - P01 CA55819/CA/NCI NIH HHS/United States
GR  - R01 CA96569/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PT  - Review
PL  - United States
TA  - Leuk Lymphoma
JT  - Leukemia & lymphoma
JID - 9007422
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (Cancer Vaccines)
SB  - IM
MH  - Antigen-Presenting Cells/immunology
MH  - Antigens, Neoplasm/immunology
MH  - Cancer Vaccines
MH  - Clinical Trials as Topic
MH  - Dendritic Cells/*cytology
MH  - Disease-Free Survival
MH  - Humans
MH  - Immunotherapy/*methods
MH  - Multiple Myeloma/*therapy
MH  - T-Lymphocytes/metabolism
MH  - Time Factors
RF  - 76
EDAT- 2004/02/13 05:00
MHDA- 2004/09/10 05:00
CRDT- 2004/02/13 05:00
PHST- 2004/02/13 05:00 [pubmed]
PHST- 2004/09/10 05:00 [medline]
PHST- 2004/02/13 05:00 [entrez]
AID - 10.1080/1042819031000116599 [doi]
PST - ppublish
SO  - Leuk Lymphoma. 2003 Dec;44(12):2031-8. doi: 10.1080/1042819031000116599.